144 related articles for article (PubMed ID: 38169969)
1. CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.
Schoumacher C; Derangère V; Gaudillière-Le Dain G; Huppe T; Rageot D; Ilie A; Vienot A; Borg C; Monnien F; Bibeau F; Truntzer C; Ghiringhelli F;
Oncoimmunology; 2024; 13(1):2294563. PubMed ID: 38169969
[TBL] [Abstract][Full Text] [Related]
2. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
[No Abstract] [Full Text] [Related]
3. RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer.
Ledys F; Klopfenstein Q; Truntzer C; Arnould L; Vincent J; Bengrine L; Remark R; Boidot R; Ladoire S; Ghiringhelli F; Derangere V
J Immunother Cancer; 2018 Nov; 6(1):123. PubMed ID: 30454021
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis.
Orhan A; Vogelsang RP; Andersen MB; Madsen MT; Hölmich ER; Raskov H; Gögenur I
Eur J Cancer; 2020 Jun; 132():71-84. PubMed ID: 32334338
[TBL] [Abstract][Full Text] [Related]
5. Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
McGuigan AJ; Coleman HG; McCain RS; Kelly PJ; Johnston DI; Taylor MA; Turkington RC
J Pathol Clin Res; 2021 Mar; 7(2):99-112. PubMed ID: 33481339
[TBL] [Abstract][Full Text] [Related]
6. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
7. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.
Lee SH; Hwang DW; Yoo C; Kim KP; Kang S; Jeong JH; Oh D; Song TJ; Lee SS; Park DH; Seo DW; Park JH; Song KB; Lee JH; Lee W; Park Y; Kwak BJ; Chang HM; Ryoo BY; Kim SC
Cancer Res Treat; 2023 Jul; 55(3):956-968. PubMed ID: 36915253
[TBL] [Abstract][Full Text] [Related]
8. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.
Estrella JS; Rashid A; Fleming JB; Katz MH; Lee JE; Wolf RA; Varadhachary GR; Pisters PW; Abdalla EK; Vauthey JN; Wang H; Gomez HF; Evans DB; Abbruzzese JL; Wang H
Cancer; 2012 Jan; 118(1):268-77. PubMed ID: 21735446
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
[TBL] [Abstract][Full Text] [Related]
10. The association between CD3
Panahi M; Rezagholizadeh F; Mollazadehghomi S; Farhangnia P; Niya MHK; Ajdarkosh H; Tameshkel FS; Heshmati SM
Cancer Treat Res Commun; 2023; 35():100699. PubMed ID: 36996584
[TBL] [Abstract][Full Text] [Related]
11. Infiltration of CD3+ and CD8+ lymphocytes in association with inflammation and survival in pancreatic cancer.
Tushoski-Alemán GW; Herremans KM; Underwood PW; Akki A; Riner AN; Trevino JG; Han S; Hughes SJ
PLoS One; 2024; 19(2):e0297325. PubMed ID: 38346068
[TBL] [Abstract][Full Text] [Related]
12. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer.
He Q; Li G; Ji X; Ma L; Wang X; Li Y; Fan C
Tumour Biol; 2017 May; 39(5):1010428317697571. PubMed ID: 28475005
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.
Nejati R; Goldstein JB; Halperin DM; Wang H; Hejazi N; Rashid A; Katz MH; Lee JE; Fleming JB; Rodriguez-Canales J; Blando J; Wistuba II; Maitra A; Wolff RA; Varadhachary GR; Wang H
Pancreas; 2017 Oct; 46(9):1180-1187. PubMed ID: 28902789
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
15. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
Front Immunol; 2021; 12():790661. PubMed ID: 34925373
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E
Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602
[TBL] [Abstract][Full Text] [Related]
18. Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis.
Masuda S; Yamakawa K; Masuda A; Toyama H; Sofue K; Nanno Y; Komatsu S; Omiya S; Sakai A; Kobayashi T; Tanaka T; Tsujimae M; Ashina S; Gonda M; Abe S; Uemura H; Kohashi S; Inomata N; Nagao K; Harada Y; Miki M; Irie Y; Juri N; Kanzawa M; Itoh T; Fukumoto T; Kodama Y
Ann Surg Oncol; 2023 Sep; 30(9):5776-5787. PubMed ID: 37191859
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers.
Kim JE; Kim H; Kim B; Chung HG; Chung HH; Kim KM; Kim SH; Jeong WK; Kim YK; Min JH; Heo JS; Han IW; Shin SH; Park HC; Yu JI; Park JO; Kim ST; Hong JY; Lee SH; Lee KH; Lee JK; Lee KT; Jang KT; Park JK
Cancer Med; 2023 Apr; 12(7):7748-7761. PubMed ID: 36650632
[TBL] [Abstract][Full Text] [Related]
20. High CD8
Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]